RESEARCH

The trend of direct medical costs and associated factors in patients with chronic hepatitis B in Guangzhou, China: an eight-year retrospective cohort study

Shuo Yang1†, Ge Chen1†, Yueping Li2, Guanhai Li1, Yingfang Liang2, Feng Zhou1, Shudong Zhou1, Yi Yang1, Weidong Jia2*, Yanhui Gao1,3* and Yue Chen4

From International Conference on Health Big Data and Artificial Intelligence 2020 Guangzhou, China. 29 October - 1 November 2020

Abstract

Background: Although the expenses of liver cirrhosis are covered by a critical illness fund under the current health insurance program in China, the medical costs associated with hepatitis B virus (HBV) related diseases is not well addressed. In order to provide evidence to address the problem, we investigated the trend of direct medical costs and associated factors in patients with chronic HBV infection.

Methods: A retrospective cohort study of 65,175 outpatients and 12,649 inpatients was conducted using a hospital information system database for the period from 2008 to 2015. Generalized estimating equations (GEE) were applied to explore associations between annual direct medical costs and corresponding factors, meanwhile quantile regression models were used to evaluate the effect of treatment modes on different quantiles of annual direct medical costs stratified by medical insurances.

Results: The direct medical costs increased with time, but the proportion of antiviral costs decreased with CHB progression. Antiviral costs accounted 54.61% of total direct medical costs for outpatients, but only 6.17% for inpatients. Non-antiviral medicine costs (46.06%) and lab tests costs (23.63%) accounted for the majority of the cost for inpatients. The direct medical costs were positively associated with CHB progression and hospitalization days in inpatients. The direct medical costs were the highest in outpatients with medical insurance and in inpatients with free medical service, and treatment modes had different effects on the direct medical costs in patients with and without medical insurance.

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Hepatitis B virus (HBV) infection is a major global health concern [1]. In China, the overall annual incidence of hepatitis B was 80.63 per 10 million during the period from 2004 to 2013 [2], and a recent systematic review of global HBV infection indicated that China was an intermediate endemic area for the infection, with a combined prevalence of HBV infection of 5.7% [3]. China has the largest number of HBV infected people in the world, and there are approximately 76 million HBV carriers among the populations under the age of 60 years [4].

Patients infected with HBV are at significant risk for developing chronic hepatitis B (CHB), compensated cirrhosis, decompensated cirrhosis, and primary hepatocellular carcinoma (HCC) [5]. CHB and its related diseases pose a substantial economic burden on patients and their families [6, 7], and medical costs comprise the majority portion of the total expenditures and increase with disease progression [6, 8–13].

However, there was high heterogeneity for the estimates of medical costs due to HBV infection from previous studies [8–16] and cross-sectional or short term data did not provide a trajectory of the costs over time. This study aimed to estimate the direct medical costs due to HBV infection and its complications, costs components and associated factors based on data from a real-world retrospective cohort of CHB patients for the period from January 1, 2008 to December 31, 2015 in Guangzhou, China. The results can be utilized in cost-effectiveness evaluation of treatment and help healthcare providers and policy makers for their efforts in improving patients’ health conditions and reducing medical costs.

Methods
Study design and study population
Two retrospective cohorts of outpatients and inpatients were created using the electronic medical records from the hospital information system (HIS) of the Guangzhou Eighth People’s Hospital, the largest specialized infectious disease hospital in Guangdong Province, China. This cohort included inpatients and outpatients with HBV related conditions including CHB, cirrhosis (including compensated and decompensated cirrhosis) and HCC during the period from January 1, 2008 to December 31, 2015, who were identified according to the International Classification of Disease, 10th Revision (ICD-10) codes (CHB: B18.0 and B18.1, cirrhosis: K74.601 and K74.602, HCC: K76.814). Patients co-infected with hepatitis A, hepatitis C, hepatitis D, hepatitis E, HIV or cytomegalovirus (CMV) were excluded from this study. Patients admitted to the hospital due to pregnancy or other diseases including glomerulonephritis, uremia, metabolic syndrome, tumor, severe cardiovascular diseases were also excluded.

Statistical analysis
The direct medical costs per person per year were taken as the analysis unit. Mean, median and upper and lower quartiles of annual direct medical costs were calculated, and the costs were expressed in RMB in the year of 2015 and were adjusted by a discount rate of 5% per year. Average annual direct medical costs, costs components and corresponding proportions of costs components in total direct medical costs were also calculated for inpatients and outpatients by different disease stages.

Because of extremely positive partial peak distribution and individual correlation of medical costs between multiple visits/admissions for individual patients, generalized estimating equations and quantile regression were used in this study.

Conclusions: CHB patients had a heavy economic burden in Guangzhou, China, which increased over time, which were influenced by payment mode and treatment mode.

Keywords: Chronic hepatitis B, Direct medical costs, Generalized estimating equations, Quantile regression
patients, generalized estimating equations (GEE) [17] with log link function and gamma error distribution were applied to explore the associations between determinants and direct medical costs. Quantile regression models [18] were used to assess the effect of treatment modalities on direct medical costs for patients according to medical insurance status. Quantile regression makes no requirement for the distribution of random errors, and is particularly effective when the distribution is asymmetric, thick-tailed, or deleted. The statistical analyses were conducted separately for outpatients and inpatients by using SAS 9.4 (SAS Institute, Cray, NC).

Results

General characteristics of the study population

A total of 65,175 outpatients and 12,649 inpatients were retrieved from the Guangzhou Eighth People’s Hospital database for the study period between January 1, 2008 and December 31, 2015 (Fig. 1). General characteristics of the outpatients and the inpatients by disease stages were detailed in Table 1. Approximate
90% outpatient visits and 57% inpatient admissions were due to CHB, 9% and 27% were due to cirrhosis, and 1% and 16% were due to HCC. About 75% of these patients were male and the proportion of patients aged 40 to 60 accounted for approximately 50%. Self-payment and medical insurance were the main payment modes. Table 1 also shows the proportions of patients received prescriptions for antiviral drugs, hepatoprotective drugs, traditional Chinese medicine and antifibrotic medicine for outpatients and inpatients.

### Table 1 Characteristics and medication use of outpatients and inpatients [N (%)]

| Characteristics                  | CHB | Cirrhosis | HCC | Total |
|----------------------------------|-----|-----------|-----|-------|
| **Outpatients**                  |     |           |     |       |
| N                                | 58,857 (90.31) | 5610 (8.61) | 708 (1.09) | 65,175 (100.00) |
| Age (years)<sup>a</sup>          | 35.07 ± 12.24 | 48.90 ± 12.95 | 52.62 ± 13.08 | 36.45 ± 13.02 |
| Gender<sup>b</sup>               |     |           |     |       |
| Male                             | 41,816 (71.08) | 4241 (75.61) | 603 (85.17) | 46,660 (71.62) |
| Female                           | 17,015 (28.92) | 1368 (24.39) | 105 (14.83) | 18,488 (28.38) |
| Payment mode                     |     |           |     |       |
| Self-payment                     | 39,481 (67.08) | 3958 (70.55) | 607 (85.73) | 44,046 (67.58) |
| Medical insurance                | 15,419 (26.20) | 1314 (23.42) | 75 (10.59) | 16,808 (25.79) |
| Free medical service             | 3951 (6.71) | 338 (6.02) | 26 (3.67) | 4315 (6.62) |
| Others<sup>c</sup>               | 6 (0.01) | 0 (0.00) | 0 (0.00) | 6 (0.01) |
| Antiviral medicine               |     |           |     |       |
| Yes<sup>d</sup>                  | 25,525 (43.37) | 2803 (49.96) | 172 (24.29) | 28,500 (43.73) |
| No                               | 33,332 (56.63) | 2807 (50.04) | 536 (75.71) | 36,675 (56.27) |
| IFN                              |     |           |     |       |
| Yes<sup>d</sup>                  | 4092 (6.95) | 44 (0.78) | 0 (0.00) | 4136 (6.35) |
| No                               | 54,765 (93.05) | 5566 (99.22) | 708 (100.00) | 61,039 (93.65) |
| NA<sup>e</sup>                   |     |           |     |       |
| Yes<sup>d</sup>                  | 22,811 (38.76) | 2778 (49.52) | 172 (24.29) | 25,761 (39.53) |
| No                               | 36,046 (61.24) | 2832 (50.48) | 536 (75.71) | 39,414 (60.47) |
| Hepatoprotective drugs           |     |           |     |       |
| Yes<sup>d</sup>                  | 32,247 (54.79) | 2447 (43.62) | 207 (29.24) | 34,901 (53.55) |
| No                               | 26,610 (45.21) | 3163 (56.38) | 501 (70.76) | 30,274 (46.45) |
| Chinese medicine                 |     |           |     |       |
| Yes<sup>d</sup>                  | 26,172 (44.47) | 3068 (54.69) | 255 (36.02) | 29,495 (45.26) |
| No                               | 32,685 (55.53) | 2542 (45.31) | 453 (63.98) | 35,680 (54.74) |
| Anti-fibrotic medicine           |     |           |     |       |
| Yes<sup>d</sup>                  | 9142 (15.53) | 3298 (58.79) | 214 (30.23) | 12,654 (19.42) |
| No                               | 49,715 (84.47) | 2312 (41.21) | 494 (69.77) | 52,521 (80.58) |
| Visiting times<sup>f</sup>       |     |           |     |       |
| Yes<sup>d</sup>                  | 4 (2–14) | 4 (2–15) | 1 (1–3) | 4 (2–14) |
| No                               | 1 (1–2) | 1 (1–1) | 1 (1–1) | 1 (1–1) |

<sup>a</sup> Mean ± STD  
<sup>b</sup> Gender: outpatients have 27 gender missing values  
<sup>c</sup> Others: commercial insurance and cooperative medical service, etc.  
<sup>d</sup> Yes: patients received prescription for corresponding drugs in this year

### Average annual direct medical costs and costs components from 2008 to 2015

The average annual direct medical costs for outpatients and inpatients were 3731.05 and 12,967.77 RMB for CHB; 5871.55 and 23,869.57 RMB for cirrhosis; and 3734.82 and 27,996.54 RMB for HCC, respectively. Table 2 showed the components of average annual direct medical costs for patients with different disease stages. For outpatients, use of antiviral drugs (54.61%) was the costliest component, followed by non-antiviral...
Table 2 Average annual direct medical costs and cost components by disease states (RMB)

| Disease states | Total costs | Lab tests and imaging examinations costs (%) | Antiviral therapy costs (%) | Other medicine costs (%) | Bed and nursing costs (%) | Other costs (%) | Hepatoprotective drugs costs (%) | Chinese medicine costs (%) | Anti-fibrotic medicine costs (%) |
|----------------|-------------|---------------------------------------------|----------------------------|-------------------------|--------------------------|----------------|--------------------------------|-------------------------------|--------------------------------|
| Outpatients    |             |                                             |                            |                         |                          |                |                                |                               |                                |
| CHB            | 3731.05     | 612.59 (16.42)                             | 2115.80 (56.71)            | 973.74 (26.10)          | –                        | 26.77 (0.72) | 402.26 (10.78)                | 321.68 (8.62)                | 192.66 (5.16)                 |
| Cirrhosis      | 5871.55     | 791.89 (13.49)                             | 2762.03 (47.04)            | 2280.05 (38.83)         | –                        | 35.57 (0.61) | 352.18 (6.00)                | 1171.40 (19.95)              | 1317.66 (22.44)              |
| HCC            | 3734.82     | 736.14 (19.71)                             | 1347.16 (36.07)            | 1597.73 (42.78)         | –                        | 51.37 (1.38) | 230.27 (6.17)                | 897.42 (24.03)               | 782.29 (20.95)               |
| All            | 4019.52     | 638.01 (15.87)                             | 2195.07 (54.61)            | 1156.11 (28.76)         | –                        | 28.20 (0.70) | 393.77 (9.80)                | 442.03 (11.00)               | 350.25 (8.71)               |
| Inpatients     |             |                                             |                            |                         |                          |                |                                |                               |                                |
| CHB            | 12,967.77   | 3582.27 (27.62)                           | 1248.97 (9.63)             | 5549.54 (42.79)         | 1185.32 (9.14)           | 1401.66 (10.81)| 2827.57 (21.80)               | 274.13 (2.11)                | 80.71 (0.62)                 |
| Cirrhosis      | 23,869.57   | 5352.03 (22.42)                           | 1223.75 (5.13)             | 11,798.04 (49.43)       | 1479.03 (6.20)           | 4016.72 (16.83)| 3352.95 (14.05)               | 781.21 (3.27)                | 534.99 (2.24)               |
| HCC            | 27,996.54   | 5513.45 (19.69)                           | 765.67 (2.73)              | 12,775.57 (45.63)       | 1294.78 (4.62)           | 7647.07 (27.31)| 2594.88 (9.27)               | 993.19 (3.55)                | 441.90 (1.58)               |
| All            | 18,801.96   | 4443.79 (23.63)                           | 1159.99 (6.17)             | 8659.90 (46.06)         | 1292.78 (6.87)           | 3245.50 (17.26) | 2947.68 (15.68)               | 548.87 (2.92)                | 279.21 (1.49)               |

medications (28.76%, including 9.80% of hepatoprotective drugs, 11.00% of traditional Chinese medicine and 8.71% anti-fibrotic drugs). For inpatients, use of non-antiviral medications contributed 46.06% (including 15.68% of hepatoprotective drugs, 2.92% of traditional Chinese medications and 1.49% anti-fibrotic drugs) and lab tests and imaging examinations contributed 23.63% of the total costs. Antiviral medication costs accounted for only 6.17% of the total costs for inpatients.

The direct medical costs were mostly increasing from the year of 2008 to 2015 for all the patients (Fig. 2). The proportion of antiviral drug use was decreasing with the disease stage (Fig. 3). The costliest component was antiviral drug use for outpatients and use of non-antiviral drugs for inpatients. Among outpatients, the proportion of antiviral drug use increased, whereas the proportion of non-antiviral drug use and lab test decreased over time.

Associated factors for annual direct medical costs
Table 3 showed the factors associated with annual direct medical costs in outpatients and inpatients. Male and older patients had significantly higher costs as compared with female and younger patients ($P < 0.0001$). For outpatients, those with medical insurance had the highest costs, followed by those who paid out-of-pocket and those with free medical service. For inpatients, those with free medical service had the highest costs, followed by patients with medical insurance and those who paid out-of-pocket. Antiviral therapy ($\beta(SE) = 1.68(0.01), P < 0.0001$), hepatoprotective drugs ($\beta(SE) = 1.68(0.01), P < 0.0001$), traditional Chinese medication ($\beta(SE) = 0.22(0.01), P < 0.0001$) and anti-fibrotic medication ($\beta(SE) = 0.55(0.01), P < 0.0001$) significantly increased the direct medical costs for outpatients. Similarly, antiviral therapy ($\beta(SE) = 0.17(0.01), P < 0.0001$), hepatoprotective drugs ($\beta(SE) = 0.25(0.01), P < 0.0001$), traditional Chinese medication ($\beta(SE) = 0.17(0.01), P < 0.0001$) significantly increased the direct medical costs for inpatients. The direct medical costs were positively associated with the progression of HBV infection and hospitalization days in inpatients ($P < 0.0001$).

Figures 4 and 5 showed the results from quantile regression models for treatment modes associated with direct medical costs. In outpatients, the utilization of antiviral drugs, hepatoprotective drugs, traditional Chinese medications and anti-fibrosis drugs increased the direct medical costs of patients with or without medical insurance, and it was more so for patients with a high level of medical costs. In inpatients, the utilization of antiviral drugs significantly increased the direct medical costs. The 25%, 50% and 75% of quantile regression coefficients for antiviral treatment associated with the direct medical costs were positively associated with the progression of HBV infection and hospitalization days in inpatients ($P < 0.0001$).
the influences of hepatoprotective drugs, traditional Chinese medication and anti-fibrosis drugs on the direct medical costs were similar for inpatients with and without medical insurance.
Discussion
Our study found that the average annual direct medical costs for patients with HBV related diseases in Guangzhou were substantial and the annual direct medical costs were increasing for both outpatients and inpatients from 2008 to 2015. Guangzhou is the capital city of Guangdong Province, Southeast China, is the forefront of China’s economic and social development. According to the annual report of the bureau of statistics in Guangzhou, the disposable personal income was 46,734.60 RMB in
| Factors                      | Outpatients |                                  | Inpatients |                                  |
|------------------------------|-------------|----------------------------------|------------|----------------------------------|
|                              | Cost (mean) | Cost (M(Q₁–Q₃)) | β        | SE | P                        | Cost (mean) | Cost (M(Q₁–Q₃)) | β        | SE | P                        |
| Gender                       |             |                    |          |    |                          |             |                    |          |    |                          |
| Male                         | 4198.92     | 1909.98 (664.50–5813.24) | Ref      |    |                          | 19,449.20   | 12,004.35 (6765.12–22,922.24) | Ref      |    |                          |
| Female                       | 3330.35     | 1463.41 (553.91–4616.10) | −0.07    | 0.01 | <0.0001                  | 16,701.86   | 10,604.72 (6300.63–19,184.97) | −0.06    | 0.01 | <0.0001                  |
| Age                          |             |                    |          |    |                          |             |                    |          |    |                          |
| 18–29                        | 3638.45     | 1398.60 (541.19–4592.04) | Ref      |    |                          | 12,173.28   | 8263.53 (5078.25–13,815.65) | Ref      |    |                          |
| 30–39                        | 4171.64     | 1802.48 (636.68–5708.63) | 0.03     | 0.01 | 0.0068                   | 15,866.61   | 10,525.78 (6150.71–18,696.58) | 0.11     | 0.02 | <0.0001                  |
| 40–49                        | 4336.78     | 2210.05 (734.33–6163.25) | −0.01    | 0.01 | 0.8982                   | 21,198.46   | 13,456.04 (7303.28–25,995.43) | 0.22     | 0.02 | <0.0001                  |
| 50–59                        | 4185.27     | 2093.56 (737.78–5985.38) | −0.05    | 0.01 | 0.0008                   | 23,465.83   | 15,388.61 (8448.31–20,968.38) | 0.24     | 0.02 | <0.0001                  |
| ≥60                          | 3847.18     | 1893.67 (667.02–5364.38) | −0.10    | 0.02 | <0.0001                  | 26,063.35   | 16,874.79 (9145.88–31,415.35) | 0.28     | 0.02 | <0.0001                  |
| Payment mode                 |             |                    |          |    |                          |             |                    |          |    |                          |
| Self-payment                 | 3712.91     | 15,59.49 (584.49–4887.64) | ref      |    |                          | 17,784.66   | 11,168.72 (5287.71–21,266.31) | Ref      |    |                          |
| Medical insurance            | 5066.04     | 2862.03 (882.33–7450.20) | 0.11     | 0.01 | <0.0001                  | 20,808.66   | 12,406.73 (7273.45–23,788.23) | −0.04    | 0.01 | 0.0018                   |
| Free medical service         | 2784.96     | 11,40.70 (445.45–3205.32) | −0.19    | 0.02 | <0.0001                  | 21,428.33   | 14,006.00 (8526.01–25,444.22) | −0.14    | 0.03 | <0.0001                  |
| Others                       | 852.51      | 706.93 (403.26–1084.77) | −0.14    | 0.13 | 0.9283                  | 13,166.87   | 8766.42 (5691.22–17,312.19) | −0.09    | 0.07 | 0.1810                   |
| Antiviral medicine           |             |                    |          |    |                          |             |                    |          |    |                          |
| No                           | 1475.46     | 771.42 (402.67–1692.61) | ref      |    |                          | 14,125.19   | 8132.11 (4841.38–15,879.36) | Ref      |    |                          |
| Yes                          | 7020.08     | 5357.05 (2301.01–9959.00) | 1.68     | 0.01 | <0.0001                  | 22,221.89   | 14,401.12 (8643.15–26,762.65) | 0.17     | 0.01 | <0.0001                  |
| Hepatoprotective drugs       |             |                    |          |    |                          |             |                    |          |    |                          |
| No                           | 3783.10     | 778.77 (408.76–1706.41) | ref      |    |                          | 6,774.95    | 4308.40 (3300.17–7352.18) | Ref      |    |                          |
| Yes                          | 4263.31     | 5356.04 (2306.41–9944.59) | 0.51     | 0.01 | <0.0001                  | 19,695.67   | 12,342.43 (7275.06–23,087.47) | 0.25     | 0.02 | <0.0001                  |
| Anti-fibrotic medicine       |             |                    |          |    |                          |             |                    |          |    |                          |
| No                           | 3386.25     | 131.54 (517.40–4521.88) | Ref      |    |                          | 13,039.13   | 8274.40 (4994.98–15,263.26) | ref      |    |                          |
| Yes                          | 5239.27     | 2859.98 (1098.96–7248.16) | 0.22     | 0.01 | <0.0001                  | 23,146.67   | 14,760.32 (8639.26–28,007.82) | 0.17     | 0.01 | <0.0001                  |
| Disease stages               |             |                    |          |    |                          |             |                    |          |    |                          |
| CHB                         | 3731.05     | 1570.04 (587.43–4954.84) | ref      |    |                          | 12,967.77   | 9094.66 (5550.94–15,133.85) | Ref      |    |                          |
| Cirrhosis                   | 5871.53     | 3823.50 (1229.07–8027.62) | 0.14     | 0.01 | <0.0001                  | 23,869.57   | 15,703.35 (8847.61–28,033.55) | 0.40     | 0.03 | <0.0001                  |
| HCC                         | 3734.82     | 1676.06 (6107.75–4737.08) | 0.10     | 0.05 | 0.0443                  | 27,996.54   | 20,271.02 (9274.40–36,742.64) | 0.62     | 0.03 | <0.0001                  |
| Length of stay (days)        |             |                    |          |    |                          |             |                    |          |    |                          |
| <10                          | –           | –                  | –        |    |                          | 663.30      | 5304.68 (3879.56–7584.06) | ref      |    |                          |
| 10–20                        | –           | –                  | –        |    |                          | 13,584.70   | 10,574.83 (7767.96–15,979.52) | 0.61     | 0.01 | <0.0001                  |
| >20                          | –           | –                  | –        |    |                          | 33,436.70   | 23,685.30 (15,248.07–41,339.85) | 1.47     | 0.02 | <0.0001                  |

a Gender: 60 were missing for outpatients
b Others: commercial insurance and cooperative medical service, etc.
c Yes: patients received prescription for corresponding drugs
d SE: standard error
2015 [19]. As for CHB patients, the direct medical costs of the three disease stages accounted for 7.98–12.56% of individual income annually on average for outpatients and 27.75–59.91% for inpatients in Guangzhou, which is slightly higher than results of 5–40% from a study from Beijing in 2012 [20].

Our results indicated that treatment mode was an important determinant of annual direct medical costs for CHB patients. Antiviral therapy is the most key to favorable prognosis for CHB-related disease patients, especially in the early stages of HBV infection [21]. The annual direct medical costs for patients with antiviral therapy were consistently higher than those without antiviral treatment (fivefold for outpatients vs 1.2-fold for inpatients), and the annual costs of antiviral medications and its percentage of the total medical costs descended with disease progression. The antiviral medications accounted for 65.50% of the medical costs for CHB outpatients but only 45.75% for HCC outpatients. Patients with cirrhosis and HCC utilized more medical resources other than antiviral medications. Compared with outpatients, the proportion of antiviral treatment costs in inpatients were lower and only accounted for a small percentage of the direct medical costs for each disease stage, while other medications and lab tests and imaging examinations made up a major percentage of the costs.

CHB patients acquire a higher proportion of antiviral treatment in the early disease stage to prevent the progression of liver diseases. However, this study shows that the antiviral utilization rate was not high, only 43.73% for outpatients and 57.62% for inpatients. A study from five European countries (including Germany, France, Turkey, Poland and Romania) showed that the antiviral utilization rate was 44.75% [22]. Similarly, a study from Beijing reported the antiviral utilization rate was 50.00% for outpatients and 61.80% for inpatients [20]. The reasons for the low antiviral utilization rate should be further studied.

To effectively protect the liver of patients is one challenge for the medical and pharmaceutical professions [23, 24]. Available chemical drugs used for the treatment of liver disease could have a variety of adverse effects and damage the liver. Hepatoprotective drugs have the function of protecting liver, reducing transaminase and enhancing immunocompetence, thus it has been recommended as an adjuvant therapy for the treatment of chronic hepatitis B [4, 25]. In our study, 53.55% of outpatients and 94.40% received hepatoprotective drugs treatment, and 19.42% of outpatients and 29.16% received anti-fibrosis drugs. Hepatoprotective drugs of traditional Chinese medicine (TCM) [4] is popular in China, especially for CHB patients who fail to recover and seek alternative therapy [8, 26]. Our study showed that 45.26% of outpatients and 57.77% of inpatients received TCM treatment.

Health insurance status is an important influencing factor for medical costs [20, 27, 28]. The direct medical costs were the highest for outpatients with medical insurance and for inpatients with free medical service. Quantile regression showed that the effect of treatment mode on medical expenses was different for patients with different medical insurance status, especially for inpatients since free medical service and health insurance policies often provide a higher proportion of reimbursement for inpatients than for outpatients. Patients are motivated to be hospitalized to receive antiviral therapy or to have expensive tests for acquiring more reimbursement. Insurance policies should be modified to avoid the waste of medical resources.

In this study, patients with medical insurance and those out-of-pocket were accounted for 67.76% and 26.13% of the total population, respectively. There are still medical insurance policy differences for the different CHB patients now. Since 2008, health insurance policy has experienced a series of changes in Guangzhou. The Outpatient Medical Insurance Fund Policy was implemented in Guangzhou on August 1, 2008, that provided monthly quota payment for patients. Until October 1, 2013, both urban and rural residents were paid with CHB patients 100 RMB per month by this Fund. The payment increased to 400 RMB per month on January 1, 2015. Our previous studies have shown that those policy changes could promote the utilization of antiviral drugs in patients with CHB [29].

In the long run, the insurance system should be improved to narrow the gap between different medical insurance policy, and it is important to gradually enlarge the outpatient coverage and improve utilization of antiviral drugs. Meanwhile, HBV diagnosis, prevention and treatment behavior should be regulated and strengthened to reduce the economic burden of CHB patients, safeguarding their health interests.

This was a retrospective cohort study based on medical records of CHB patients from one hospital and has some limitations. First, patients might visited other hospitals or pharmacies and the medical costs might be underestimated. Second, it is difficult to distinguish treatment-naive patients with treatment-experienced patients, and therefore, switch or add-on treatments were not considered. Third, the retrospective study design could result in incomplete information. Fourth, our data only came from one hospital. However, Guangzhou Eighth People’s Hospital is the earliest and the only specialized liver disease hospital in Guangdong, and 8-year retrospective cohort of CHB showed stable and adequate cases in this hospital. Except hepatitis B-related HCC patients, it is to a
certain extent representative for patients with CHB and cirrhosis. Other potential confounding factors such as education, income and severity of the disease were not taken into account in this study.

Conclusion
CHB patients had a heavy economic burden that continued to be intensified. Annual direct medical costs for CHB patients increased significantly as the disease stage progressed although the proportion of the antiviral medication costs decreased. Antiviral therapy costed the most
for CHB outpatients but for inpatients, non-antiviral medications and lab tests and imaging examinations were main components of the direct medical costs. Treatment patterns and medical insurance policies were main influencing factors of the annual direct medical costs. Early antiviral treatment could reduce the economic burden of CHB patients, and rational drug utilization and expanding medical insurance coverage might reduce the direct medical costs for CHB patients.
Abbreviations
HBV: Hepatitis B virus; CHB: Chronic hepatitis B; HCC: Hepatocellular carcinoma; GEE: Generalized estimating equations; HIS: Hospital information system; ICD: International classification of disease; CMV: Cytomegalovirus; IFN: Interferon; LAM: Lamivudine; ADV: Adefovir dipivoxil; ETF: Entecavir; LdT: Telbivudine; TDF: Tenofovir; TCM: Traditional Chinese medicine; DRGs: Diagnosis related groups.

Acknowledgements
The authors thank all patients who took part in this study. The authors are grateful to the doctors of Guangzhou Eighth people’s Hospital.

About this supplement
This article has been published as part of BMC Medical Informatics and Decision Making Volume 21, Supplement 2 2021: Health Big Data and Artificial Intelligence. The full contents of the supplement are available at https://bmcmedinformdecismak.biomedcentral.com/articles/supplements/volume-21-supplement-2.

Authors’ contributions
SY played a role in conceptualization, data collection, analysis and drafted the initial manuscript. GC, YL and GL conceptualized the design and supervised the study. YL and YG provided their valuable guidance in the study methodology. SZ, YY and WJ reviewed the manuscript. FZ and YC assisted in the conduct of the study. All authors read and approved the final manuscript.

Funding
This study was supported by the National Natural Science Foundation of China (No.71573059) and Guangdong Provincial Engineering Research Center of Public Health Detection and Assessment (No.219GCKX012).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study protocol was reviewed and approved by ethical review board of Guangdong Pharmaceutical University and written informed consent was obtained from each study participant. Permission letter also obtained from Guangzhou Eighth people's Hospital. Names of participants and other personal identifiers were not included in the data collection tool.

Consent for publication
Not applicable.

Competing interests
No conflict of interest exists in the submission of this manuscript.

Author details
1 Department of Epidemiology and Medical Statistics, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.
2 Guangzhou Eighth People’s Hospital, Guangzhou, Guangdong, China.
3 Department of Public Health and Preventive Medicine, School of Medicine, Jinan University, Guangzhou, Guangdong, China. 4 School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Received: 14 January 2021 Accepted: 9 February 2021
Published: 30 July 2021

References
1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology (Baltimore, MD). 2009;50(3):661–2.
2. Zhang M, Yuan Y, Mao P, et al. Analysis on morbidity and mortality of viral hepatitis in China, 2004–2013. Chin J Epidemiol. 2015;36(2):144–7.
3. Schweitzer A, Horn J, Mlkojiczzyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet (London, England). 2015;386(10003):1546–55.
4. Lu FM, Zhuang H. Management of hepatitis B in China. Chin Med J. 2009;122(1):3–4.
5. Iloeje UH, Yang H, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678–86.
6. Kowdley KV. The cost of managing chronic hepatitis B infection: a global perspective. J Clin Gastroenterol. 2004;38:513–13.
7. Chen CJ, Yang H, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73.
8. Zhang S, Ma Q, Liang S, et al. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China. J Viral Hepatitis. 2015;22(3):202–10.
9. Li Y, Wang H, Zhang W, et al. Investigation on the cost of patients with different outcomes related to hepatitis B virus infection in Beijing. J Clin Med. 2014.
10. Lu J, Xu A, Wang J, et al. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong China. BMC Health Serv Res. 2013;13:37.
11. Liang S, Zhang SX, Qi-Shan MA. Study on the Direct Economic Burden of Hepatitis B and its Economic Impact on Family in Shenzhen City. Chinese Health Economics. 2011.
12. Hu M, Chen W. Assessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China. Value Health. 2009;12(6):589–92.
13. Ma QS, Zou HY, Zhang SX, et al. Estimation on the intangible cost and influencing factors for patients with hepatitis B-related diseases. Chin J Epidemiol. 2011;32(8):764–7.
14. Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology (Baltimore, MD). 2014;60(6):2099–108.
15. Zhang Y, Wu J, Li Y. Review on economic burden of hepatitis B among Chinese mainland population. Chin Rural Health Serv Adm. 2012;3(11):1115–8.
16. Xiao J, Zhang J, Wu C, et al. Impact of hepatitis B vaccination among children in Guangdong Province, China. Int J Infect Dis. 2012;16(9):e692–6.
17. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44(4):1049–60.
18. Koekker R, Basset G. Regression quantiles. Econometrica. 1978;46(1):33–50.
19. Guangzhou Statistics Bureau. National economic and social development statistics bulletin in 2015 in Guangzhou, China. 2016. http://tjj.gz.gov.cn/tjgb/qtjgb. Accessed 1 Apr 2016.
20. Qiu Q, Li Y, Duan XW, et al. Impact of a new reimbursement program on the treatment and reimbursement policies. Antivir Ther. 2014;19(3):245–57.
21. Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol. 2009;51(2):306–11.
22. Arama V, Leblebicioglu H, Simon K, et al. Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies. Antivir Ther. 2014;19(3):245–57.
23. Liver E. EASL clinical practice guidelines: management of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China. Value Health. 2012;15(7):167–185.
24. Liaw YF, Kao JH, Piravathisath, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B. A 2012 update. Hep Int. 2012;6(3):531–61.
25. Hou J, Wang G, Wang F, et al. Guideline of prevention and treatment for chronic hepatitis B (2nd version). J Clin Transl Hepatol. 2017;5(4):297–318.
26. Yu R, Fan R, Hou J. Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China. Front Med. 2014;8(2):135–44.
27. Che YH, Chongsuvivatwong V, Li L, et al. Financial burden on the families of patients with hepatitis B virus-related liver diseases and the role of public health insurance in Yunnan province of China. Public Health. 2015;130:13–20.
28. Xiao J, Lin H, Tao L, et al. Disease burden from hepatitis B virus infection in Guangdong Province, China. Int J Environ Res Public Health. 2015;12(11):4055–67.
29. Zhou F, Jia WD, Yang S, et al. Antiviral drug utilization and annual expenditures for patients with chronic HBV infection in Guangzhou, China, in 2008–2015. Antivir Ther. 2019;24(6):405–16.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.